According to a recent market study published by Growth Market Reports, titled, “Subdermal Contraceptive Implants Market by type, by end user and Regions: Size, Share, Trends and Opportunity Analysis, 2019-2029”, the market was valued at US$ 966.4 Million in 2021 and is expected to grow at a moderate growth rate of 8.4% by the year 2028. Increasing unintended pregnancies and technological advancements in contraceptive devices are expected to propel the subdermal contraceptive implant market.

Request a free sample copy @ https://growthmarketreports.com/request-sample/4305

A subdermal contraceptive implant is a small, flexible rod that is inserted under the skin of the inner upper arm. It slowly releases a progestogen hormone to prevent pregnancy for a long period of time which ranges from three to five years. One of the common hormones used in contraceptive implants is a progestogen, which is similar to the natural hormone progesterone that is synthesized by the female body. The implants are inserted subdermally, under local anesthesia with the use of a trocar, in the inner aspect of the non-dominant arm.

The implant works by preventing the release of the egg from the ovary (blocking the ovulation cycle) and restricts the entry of sperm to the uterus (womb) by thickening the cervical mucus.

The subdermal contraceptive implant is an effective method of birth control with a scientifically proven efficacy of more than 99% indicating that fewer than 1 in every 100 women using the implant method gets impregnated. Hence, it is one of the safest contraceptive options owing to the low failure rate. However, the effectiveness of subdermal contraceptive implants reduces due to the effect of other medications consumed simultaneously. These include some of the medicines used to treat HIV, epilepsy, and tuberculosis (TB), and other high concentrate medicine.

The subdermal contraceptive implants market is expected to witness a decline in year-on-year growth for 2020 as compared to for the previous year 2019. Interruption in the supply chain of valves across the globe due to the spread of COVID-19 has a moderate negative impact on product sales. Thus, the import and export of valves have witnessed a slight decrease in sales in 2021. The partial closing of manufacturing units and retail centers in the first and second quadrants of 2020 had a significant impact on the sales of the valves. Moreover, inadequate raw material supply and lack of available workforce for the production of valves in the first and second quadrant of 2020 had hampered the market growth 2021.

As per Growth Market Reports industry analyst Raksha Sharma, “The subdermal contraceptive implants market is anticipated to witness significant growth during the forecast period 2021-2029. The subdermal contraceptive implant has no serious side effects. Major side effects associated with the use of contraceptive implants are changes in frequency, duration, and amount of menstrual bleeding patterns. Some rare and minor side effects reported are infection at the site of the implant and ovarian cyst. All symptoms of side effects are temporary and fade out once the body gets metabolically adjusted to the implanted contraceptive device.

The continuation rate of subdermal contraceptive implant is higher, indicating continued use of the product after implanting it. According to research conducted by Cochrane Review, more than 80% of women continue the use their implant over two years of implantation. Various clinical trials and observational studies in a number of countries reported the continuation rates for implants to range between 78% to 96% at one year, and between 50% to 86% at three years. The key players are engaged in advertising their valves through social media platforms including Instagram, Facebook, and Twitter.”

The Coronavirus disease 2019 (COVID-19) pandemic has highlighted economic disparities in the global demand in the crises of global interdependence and governance challenges. Epidemics are isolated concerns for businesses and prospects for emerging patterns and vulnerabilities. According to the current pandemic situation, strict measures are required for monitoring the situation, which in turn, affects businesses causing unanticipated short and long-term effects.

Consequently, epidemics and pandemics are problems for the individual market and an enhancement of existing dynamics and limitations. In the long-term, COVID-19 can serve as another opportunity for manufacturers to reconsider their commitment to the supply chain in regions prone to outbreaks and to reconfigure themselves regionally. In the current scenario, COVID-19 is hampering the production process of several manufacturing industries and businesses. Moreover, trade barriers are further reducing the demand-supply of various products and services.

Key Takeaways from the Study

  • The players including Merck & Co., Inc (Organon & Co.), Bayer AG, Shanghai Dahua Pharmaceutical Co., Ltd. hold a major market share of subdermal contraceptive implants Market in the year 2021.
  • In terms of value, the Nexplanon segment accounted for a substantial share of the market in 2021 and is expected to expand at a substantial CAGR during the forecast period.
  • The market in North America is projected to expand at a significant CAGR during the forecast period, due to high regulatory approvals of the devices and increasing expenditure on the safety and reproductive health of the female population in the region.
  • The Middle East & Africa region is projected to account significant market share and is anticipated to dominate the global market in coming years owing to the Increasing preference for implantable contraceptives over traditional methods owing to their cost-effectiveness, long-term contraceptive solution, and low risk of pelvic inflammatory disease fuels the market in the region.
  • Increasing adoption of subdermal contraceptive implants due to the surging population and rising cases of unwanted pregnancies is expected to propel the market in the Asia Pacific during the forecast period.

Report Scope

Report Metric

Details

Market Value in 2021

US$ 966.4 Million

Market Growth Rate (from 2020 to 2028)

8.4%

Historical Data

2019, & 2020

Base Year

2021

Forecast Period

2022 - 2029

Units Considered

Value (US$ Million), and Volume (Mn Units)

Market Segments

By Type, By End user, and By Regions

Key Companies Profiled

Merck & Co., Inc (Organon & Co.), Bayer AG, and Shanghai Dahua Pharmaceutical Co., Ltd. among others.

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.

Target Audience

  • Supply-side: Manufacturers, raw material suppliers, and distributors
  • Demand Side: Hospitals, Clinics, Ambulatory surgical centers, and Others.
  • Regulatory Side: Concerned government authorities, and other regulatory bodies.